ArticleJournal of pregnancy2025
Assessment of Hepcidin-25 and Iron Status Profiles in Pregnant Women With Thalassemia Minor.
Article in Journal of pregnancy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The objective of the study is to compare hepcidin-25 levels between normal pregnant women and those with thalassemia minor. Methods: This prospective cohort study involved pregnant women with either normal pregnancies or thalassemia minor. Hepcidin-25 levels and iron study panels were measured at three time points: in the first trimester before the start of iron supplementation (gestational age [GA] < 14 weeks), in the third trimester (GA 28-32 weeks), and after GA 36 weeks. Results: The study included 125 pregnant women, comprising 93 with normal pregnancies and 32 with thalassemia minor. The hepcidin levels in the thalassemia minor group at GA 28-32 weeks and after GA 36 weeks were significantly lower than those in the normal pregnancy group ( Conclusion: Hepcidin-25 levels are significantly lower in pregnant women with thalassemia minor, but other iron profiles in these women are comparable to those in normal pregnancies, with no evidence of iron overload. Pregnancy with thalassemia minor is associated with mild anemia that cannot be fully corrected by iron supplementation. However, iron supplementation does not lead to iron overload and should be prescribed as part of standard antenatal care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.